Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siltuximab + best supportive care
- Development stage
- Unknown
- Lead developer
- Janssen Research & Development
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Siltuximab + best supportive care** is a combination therapy comprising siltuximab, a chimeric monoclonal antibody that selectively binds to and neutralizes interleukin-6 (IL-6), administered alongside best supportive care measures. Siltuximab blocks IL-6, a cytokine central to the pathogenesis of multicentric Castleman disease (MCD), resulting in tumor shrinkage and symptomatic improvement. Best supportive care includes all other non-curative treatments to mitigate disease symptoms and complications. This regimen is approved for the treatment of adult patients with symptomatic idiopathic multicentric Castleman disease (iMCD) who are HIV- and HHV-8-negative.
02
Targets
IL-6 (Interleukin 6)
Beyond the preview
Go deeper on siltuximab + best supportive care.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siltuximab + best supportive care.